Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of …
Full CYTHW analysis →
Competitive advantage assessment
Key risks
ROIC Below WACC or PeersROIC at 0th percentile suggests inefficient capital deployment.
Where CYTHW ranks in Drug Manufacturers - Specialty & Generic
Cyclo Therapeutics, Inc. ranks #75 of 91
scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 82%.
The widest moat in the group is Zoetis Inc. (ZTS)
at 85/100.
Moat scores for companies ranked near CYTHW in Drug Manufacturers - Specialty & Generic
How CYTHW scores on the Corporate Default defenses
Pricing Power
Score 21
· 20% of the moat score
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 11
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 19
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 6
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 20
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 33
· 15% of the moat score
Scale matters only when it converts into economics.
Cyclo Therapeutics, Inc. (CYTHW) scores 19 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #75 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 82%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (33/100) and its weakest is Capital Efficiency (6/100).
How does Cyclo Therapeutics, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?
Cyclo Therapeutics, Inc. ranks #75 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are BioAge Labs, Inc. (BIOA) at 20 just above it and InMed Pharmaceuticals Inc. (INM) at 19 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.
Why is Cyclo Therapeutics, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Cyclo Therapeutics, Inc.?
The Corporate Default template measures 6 defenses, and CYTHW scores: Pricing Power (21), Cost Advantage (11), Customer Stickiness (19), Capital Efficiency (6), Resilience (20), Scale & Market Position (33). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.